Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Takeda Pharmaceutical Company Limited is a drug manufacturers—specialty & generic business based in the US. Takeda Pharmaceutical Company shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical Company employs 47,495 staff and has a market cap (total outstanding shares value) of USD$58.7 billion.
|Latest market close||USD$18.53|
|52-week range||USD$12.43 - USD$20.93|
|50-day moving average||USD$18.5511|
|200-day moving average||USD$17.6889|
|Wall St. target price||USD$23.52|
|Dividend yield||USD$0.84 (4.51%)|
|Earnings per share (TTM)||USD$0.8115|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-24)||18.53|
|1 month (2020-09-01)||-0.11%|
|3 months (2020-07-01)||5.05%|
|6 months (2020-04-01)||25.37%|
|1 year (2019-10-01)||6.86%|
|2 years (2018-10-01)||-10.57%|
|3 years (2017-09-29)||-33.08%|
|5 years (2015-10-01)||-15.43%|
Valuing Takeda Pharmaceutical Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Takeda Pharmaceutical Company shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Takeda Pharmaceutical Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1991. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$2,201.5 billion|
|Return on assets TTM||1.45%|
|Return on equity TTM||2.5%|
|Market capitalisation||USD$58.7 billion|
TTM: trailing 12 months
There are currently 2.8 million Takeda Pharmaceutical Company shares held short by investors – that's known as Takeda Pharmaceutical Company's "short interest". This figure is 1.8% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting Takeda Pharmaceutical Company shares can be evaluated.
Takeda Pharmaceutical Company's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical Company shares currently shorted divided by the average quantity of Takeda Pharmaceutical Company shares traded daily (recently around 902097.07792208). Takeda Pharmaceutical Company's SIR currently stands at 3.08. In other words for every 100,000 Takeda Pharmaceutical Company shares traded daily on the market, roughly 3080 shares are currently held short.
However Takeda Pharmaceutical Company's short interest can also be evaluated against the total number of Takeda Pharmaceutical Company shares, or, against the total number of tradable Takeda Pharmaceutical Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical Company's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical Company shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical Company shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical Company.
Find out more about how you can short Takeda Pharmaceutical Company stock.
Dividend payout ratio: 234.59% of net profits
Recently Takeda Pharmaceutical Company has paid out, on average, around 234.59% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.51% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical Company shareholders could enjoy a 4.51% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical Company's case, that would currently equate to about $0.84 per share.
Takeda Pharmaceutical Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Takeda Pharmaceutical Company's most recent dividend payout was on 15 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 30 March 2020 (the "ex-dividend date").
Over the last 12 months, Takeda Pharmaceutical Company's shares have ranged in value from as little as $12.43 up to $20.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical Company's is 1.1301. This would suggest that Takeda Pharmaceutical Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS to uncover novel tumor-specific regulatory t-cell targets and develop unique anti-suppressor-based immunotherapies; a strategic partnership with Neurocrine Biosciences, Inc. to develop and commercialize therapies for psychiatric disorders; and Carmine Therapeutics to discover, develop, and commercialize transformative non-viral gene therapies for two rare diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.